Glass House Brands (GLAS) Income from Continuing Operations (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Income from Continuing Operations of 17006000.0 for Q1 2026, down 9.72% quarter-over-quarter from 15500000.0 in Q4 2025.
Glass House Brands (GLAS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Income from Continuing Operations for 7 consecutive years, with 17006000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations changed N/A year-over-year to 17006000.0; the TTM figure through Mar 2026 stood at 35950000.0 (changed N/A YoY), while the FY2025 annual figure was 28952000.0, down 4115.53% from the prior year.
- Income from Continuing Operations eased to 17006000.0 in Q1 2026 per GLAS's latest filing, from 15500000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15168550.0 in Q3 2022 and bottomed at 19659403246000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 2470690482803.85 across 5 years, with a median of 17006000.0 in 2026.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 100.0% — and 2023, when it slumped 58.76%.
- Glass House Brands' Income from Continuing Operations stood at 28419588.0 in 2022, then plunged by 49.89% to 42597206.0 in 2023, then jumped by 123.57% to 10039000.0 in 2024, then tumbled by 254.4% to 15500000.0 in 2025, then dropped by 9.72% to 17006000.0 in 2026.
- Business Quant data shows GLAS's Income from Continuing Operations at 17006000.0 in Q1 2026, 15500000.0 in Q4 2025, and 12188000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Glass House Brands | 825.81 Mn | 807.26 Mn | 15.77 Mn | -4.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.01 Mn |
| Dec 31, 2025 | -15.50 Mn |
| Sep 30, 2025 | -12.19 Mn |
| Jun 30, 2025 | 8.74 Mn |
| Jun 30, 2024 | 10.04 Mn |
| Dec 31, 2023 | -42.60 Mn |
| Sep 30, 2023 | 6.28 Mn |
| Jun 30, 2023 | -19,659.40 Bn |
| Mar 31, 2023 | -32.41 Mn |
| Dec 31, 2022 | -28.42 Mn |
| Sep 30, 2022 | 15.17 Mn |
| Jun 30, 2022 | -12,459.44 Bn |
| Mar 31, 2022 | -20.41 Mn |
| Dec 31, 2021 | -22.46 Mn |
| Sep 30, 2021 | -6,955.68 Bn |
| Jun 30, 2021 | -13,606.55 Bn |
| Mar 31, 2021 | -13.15 Mn |
| Dec 31, 2020 | -6.16 Mn |
| Sep 30, 2020 | -1.15 Mn |
| Mar 31, 2020 | -5.14 Mn |